Debt to Equity Ratio Chart

View Debt to Equity Ratio for VIVS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Debt to Equity Ratio Chart
Start Trial

Historical Debt to Equity Ratio Data

View and export this data back to 2011. Start Trial.
Date Value
June 30, 2026 -0.1347
March 31, 2026 -0.5141
December 31, 2025 0.1828
September 30, 2025 0.1489
June 30, 2025 0.0862
March 31, 2025 0.102
December 31, 2024 3.618
September 30, 2024 0.4234
June 30, 2024 0.1929
March 31, 2024 0.3871
December 31, 2023 0.2428
September 30, 2023 0.1897
June 30, 2023 0.1448
March 31, 2023 0.1178
December 31, 2022 0.0853
September 30, 2022 0.08
June 30, 2022 0.0756
March 31, 2022 0.0723
December 31, 2021 0.0726
September 30, 2021 0.00
June 30, 2021 0.00
March 31, 2021 0.00
December 31, 2020 0.00
September 30, 2020 0.00
June 30, 2020 0.00
Date Value
March 31, 2020 0.00
December 31, 2019 0.00
September 30, 2019 0.1485
June 30, 2019 0.1334
March 31, 2019 0.00
December 31, 2018 0.00
September 30, 2018 0.00
June 30, 2018 0.00
March 31, 2018 0.00
December 31, 2017 0.00
September 30, 2017 0.00
June 30, 2017 0.00
March 31, 2017 0.00
December 31, 2016 0.00
September 30, 2016 0.00
June 30, 2016 0.00
March 31, 2016 0.00
December 31, 2015 0.00
September 30, 2015 0.00
June 30, 2015 0.00
March 31, 2015 0.0001
December 31, 2014 0.0002
September 30, 2014 0.0002
June 30, 2014 0.0003
March 31, 2014 0.0003

Debt to Equity Ratio Definition

The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.

Read full definition.

Debt to Equity Ratio Range, Past 5 Years

View Debt to Equity Ratio Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Debt to Equity Ratio Benchmarks

View Debt to Equity Ratio Benchmarks
Start Trial
Agenus, Inc. -1.458
Amgen, Inc. 4.903
Anika Therapeutics, Inc. 0.1839
BioCryst Pharmaceuticals, Inc. -1.842
Imunon, Inc. 1.873